Therapeutic Response

17p deletion status confers therapeutic sensitivity to Venetoclax in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description
Venclyxto (venetoclax) [product information]. EMA. The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
Venclyxto (venetoclax) [product information]. EMA. The European Medicines Agency (EMA) has authorized venetoclax as a monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.